In vivo quantification of programmed death-ligand-1 expression heterogeneity in tumors using fluorescence lifetime imaging

Cancer patient selection for immunotherapy is often based on programmed death-ligand-1 (PD-L1) expression as a biomarker. PD-L1 expression is currently quantified using immunohistochemistry, which can only provide snapshots of PD-L1 expression status in microscopic regions of ex vivo specimens. In v...

Descripción completa

Detalles Bibliográficos
Autores principales: Pal, Rahul, K, Murali, Matsui, Aya, Kang, Homan, Morita, Satoru, Taniguchi, Hajime, Kobayashi, Tatsuya, Morita, Atsuyo, Choi, Hak Soo, Duda, Dan G., Kumar, Anand T.N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635296/
https://www.ncbi.nlm.nih.gov/pubmed/37961361
http://dx.doi.org/10.21203/rs.3.rs-3222037/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635296/
https://www.ncbi.nlm.nih.gov/pubmed/37961361
http://dx.doi.org/10.21203/rs.3.rs-3222037/v1

Ejemplares similares